Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.50 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.50 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.50 |
| ▸ | FER | P16591 | 1/20 | 0.50 |
| ▸ | LTK | P29376 | 1/20 | 0.50 |
| ▸ | CDK8 | P49336 | 1/20 | 0.50 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | PARP1 | P09874 | 2/20 | 0.45 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.45 |
| ▸ | PARP11 | Q9NR21 | 2/20 | 0.45 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.45 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.45 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | TNKS2 | Q9H2K2 | 3/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29380714 | 1.00 | LRRK2 (0.50) | LRRK2DYRK1BPDGFRAFERLTK | |
| SCHEMBL442677 | 0.85 | GSK3B (0.57) | LRRK2DYRK1BPDGFRAFERLTK | |
| SCHEMBL700485 | 0.82 | PARP10 (0.55) | LRRK2DYRK1BPDGFRAFERLTK | |
| Hydrochloric Acid SCHEMBL30124058 | 0.80 | PARP10 (0.53) | LRRK2DYRK1BPDGFRAFERLTK | |
| SCHEMBL30549 | 0.74 | — | — | |
| SCHEMBL30124448 | 0.74 | SMN1; SMN2 (0.48) | LRRK2DYRK1BPDGFRAFERLTK | |
| SCHEMBL18559314 | 0.74 | PARP3 (0.47) | LRRK2DYRK1BPDGFRAFERLTK | |
| SCHEMBL27335905 | 0.73 | ALDH1A1 (0.44) | LRRK2DYRK1BPDGFRAFERLTK | |
| SCHEMBL9025284 | 0.72 | PDGFRA (0.55) | LRRK2DYRK1BPDGFRAFERLTK | |
| SCHEMBL2061722 | 0.72 | LRRK2 (0.45) | LRRK2DYRK1BPDGFRAFERLTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 482 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115677600-B | 2, 3-Dihydro-quinazoline-4 (1H) -ketone derivative and preparation method and application thereof | 武汉大学人民医院（湖北省人民医院） | 2024-07-02 | — | — | CN | claimed |
| US-20240018133-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2024-01-18 | — | — | US | claimed |
| US-20240000792-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC | 2024-01-04 | — | — | US | claimed |
| CN-115160235-B | 2, 3-dihydro-quinazoline-4 (1H) -ketone compound and ultrasonic synthesis method thereof | 宜宾学院 | 2023-12-15 | — | — | CN | claimed |
| CN-115872939-A | 2,3-dihydroquinazoline-4 (1H) -ketone derivative and preparation and application thereof | 武汉科技大学 | 2023-03-31 | — | — | CN | claimed |
| CN-115677600-A | 2, 3-dihydroquinazoline-4 (1H) -ketone derivative and preparation method and application thereof | 武汉大学人民医院（湖北省人民医院） | 2023-02-03 | — | — | CN | claimed |
| CN-115160235-A | 2, 3-dihydroquinazoline-4 (1H) -ketone compound and ultrasonic synthesis method thereof | 宜宾学院 | 2022-10-11 | — | — | CN | claimed |
| CN-115028588-A | Green synthesis method of heterocyclic compound | 徐州医科大学 | 2022-09-09 | — | — | CN | claimed |
| CN-114401952-A | Substituted cycloalkyl compounds as modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2022-04-26 | — | — | CN | claimed |
| EP-3962899-A1 | SUBSTITUTED CYCLOLAKYLS AS MODULATORS OF THE INTEGRATED STRESS PATHWAY | Calico Life Sciences LLC (US) | 2022-03-09 | — | — | EP | claimed |
| EP-1534690-A1 | 2-SUBSTITUTED BICYCLIC BENZOHETEROCYCLIC COMPOUNDS AND THEIR USE AS SODIUM CHANNEL BLOCKERS | Euro-Celtique S.A. (LU) | 2005-06-01 | — | — | EP | claimed |
| EP-1507776-A1 | 2-OXO-1,3,4-TRIHYDROQUINAZOLINYL DERIVATIVES FOR THE TREATMENT OF CELL PROLIFERATION-RELATED DISORDERS | Amgen Inc. (US) | 2005-02-23 | — | — | EP | claimed |
| WO-2004013111-A1 | 2-SUBSTITUTED BICYCLIC BENZOHETEROCYCLIC COMPOUNDS AND THEIR USE AS SODIUM CHANNEL BLOCKERS | EURO-CELTIQUE S.A. (LU) | 2004-02-12 | — | — | WO | claimed |
| WO-2004013110-A1 | 4,4-DISUBSTITUTED-3,4-DIHYDRO-2(1H)-QUINAZOLINIONES USEFUL AS HIV REVERSE TRANSCRIPTASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-02-12 | — | — | WO | claimed |
| WO-2003101985-A1 | 2-OXO-1,3,4-TRIHYDROQUINAZOLINYL DERIVATIVES FOR THE TREATMENT OF CELL PROLIFERATION-RELATED DISORDERS | AMGEN INC. (US) | 2003-12-11 | — | — | WO | claimed |
| US-6274383-B1 | REACTING AN AMINO BOUND TO A SOLID SUPPORT WITH AN ISATOIC ANHYDRIDE TO FORM A 2-AMINOBENZAMIDE BOUND TO THE SUPPORT, AND THEN REACTING WITH ALDEHYDE USING A LEWIS ACID CATALYST TO FORM A 2,3-DIHYDRO-4(1H)-QUINAZOLINONE BOUND TO SUPPORT | SEPRACOR INC. | 2001-08-14 | — | — | US | claimed |
| EP-0620218-B1 | 2, 3-Dihydro-4(1H)-quinazolinones active in gastro-intestinal pathologies | ALFA WASSERMANN SPA (IT) | 1997-10-01 | — | — | EP | claimed |
| EP-0145225-B1 | RECORD MATERIAL | The Wiggins Teape Group Limited (GB) | 1989-10-04 | — | — | EP | claimed |
| US-4587538-A | Record material | THE WIGGINS TEAPE GROUP LIMITED (GB) | 1986-05-06 | — | — | US | claimed |
| EP-0145225-A2 | Record material | The Wiggins Teape Group Limited (GB) | 1985-06-19 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018133-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | LRRK2 440/4885DYRK1B 3064/4885PDGFRA 4237/4885 |
| US-20240000792-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | LRRK2 440/4885DYRK1B 3064/4885PDGFRA 4237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.